Genetic testing innovation in #ovariancancer. Pilot study by Frey MK et al. found 53% success of cascade testing when clinical team directly contacted relatives for cancer family history vs. 36% when responsibility was left to patients #gyncsm #ASCO22

Presentation by Dr. David SP Tan suggests some HRD- pts should receive bev instead of PARPi in 1L #ovariancancer if: OCCC / low grade histology, bev was commenced prior to HRD test with great response to platinum, certain molecular subtypes (CCNE1 amp) #gyncsm #ESMO22

Exciting new noninvasive test by C. Herzog et al. as reported by Journal of Clinical Oncology for #endometrialcancer screening. 97.2% accuracy in n=562 validation cohort. Potential for self-collection could improve early diagnosis #gyncsm Dr Chiara Herzog ascopubs.org/doi/full/10.12…

Three voluntary withdrawals of PARPi tx (not maintenance) in 3L+ BRCAm or HRD+ OC, based on SOLO-3 (olaparib), QUADRA (niraparib), and ARIEL-4 (rucaparib) trials. National Comprehensive Cancer Network (NCCN) guidelines updated for ola and ruca. Low impact, as PARPi in later lines are limited due to use in 1L #gyncsm

ODAC meeting for #Zejula in 2L PSOC planned on Nov. 22 based on OS detriment observed in NOVA. Important venue to discuss PARPi in PSOC and later-lines of #ovariancancer given detriment/lack of OS benefit also seen in ARIEL3, SOLO-3, and ARIEL4 #gyncsm public-inspection.federalregister.gov/2022-20524.pdf

ASCO publishes updated PARPi recommendations in #ovariancancer. Correction needed: Figure A2 in appendix should have contained HRD+ status in olaparib + bev maintenance recommendation based on PAOLA-1 label Journal of Clinical Oncology AstraZenecaUS #gyncsm ascopubs.org/doi/pdf/10.120…

Failure of IO in LACC from CALLA trial gives pause to whether tx plan is the correct approach (RT may be immunosuppressive according to timing, dose, fractioning). Worth exploring neoadjuvant instead of adjuvant IO in LACC #cervicalcancer #IGCS2022 #gyncsm

#Immunogen's mirvetuximab just became first ADC to be approved in #ovariancancer (platinum-resistant) based on SORAYA! NCCN compendia listings are expected for monotherapy in late-22 and in combo with bev in early-23. Data from confirmatory MIRASOL expected in early-23 #gyncsm

Analysis of NORA (APAC) conducted at 44% maturity showed that ISD of niraparib maint. in PSOC led to favorable OS trends across ITT, BRCAm, and non-BRCAm, despite 43% of pbo pts crossing over to PARPi! Final prespecified OS analysis expected in 2023 #ovariancancer #ESMO22 #gyncsm

Discussant: OS in NORA, NOVA, ARIEL-3 should be taken as exploratory endpt. PFS, PFS2, & TSST are sufficient for clinical decisions + support use of PARPi in 2L maint. regardless of BRCA status. EMA views OS results holistically + will not restrict 2L maint. PARPi labels #gyncsm

Citing examples from metastatic melanoma, chronic myeloid leukemia, and ovarian cancer, an interesting article from Dr. Maurie Markman on how Overall Survival is an important but not always straightforward endpoint in randomized #oncology trials onclive.com/view/overall-s… #gyncsm

Check out my latest white paper on the amazing therapeutic advances that gyn onc saw in 2022, from PARPi data and the accelerated approval of the first ADC in #ovariancancer to impressive IO + chemo results from the RUBY trial in #endometrialcancer #gyncsm axiomhcs.com/post/gyn-onc-a…

After neoadjuvant talazoparib results in BRCAm BC (Litton J.K. 2017), neoadjuvant olaparib in #ovariancancer (with mutation in BRCA1/2, RAD51C/D, or PALB2) by Shannon Westin, MD, MPH, FASCO shows outstanding surgical outcomes after only 2 cycles of olaparib, even in Stage IV pts #SGOMTG #SGO2023

Amazing to see GY018 and RUBY change SOC in #endometrialcancer! Comparable dMMR PFS data. Keep in mind... RUBY not powered for pMMR PFS. GY018 tx given for 21 mos., RUBY tx for 3 yrs. GY018 larger n size. RUBY great OS ITT data (not yet stat signif)... Incredible! #SGOMtg #gyncsm

Incredible seeing positive topline results for DUO-O, the first IO + PARPi trial to readout in #ovariancancer! Will be interesting to compare efficacy in durvalumab + olaparib vs. durva arms - what will be magnitude of benefit of IO + PARPi, given past IO failures in OC? #gyncsm

Attending The Warren Alpert Medical School #AMS_CRJC led today by medical students Ege Gungor Onal, Allegra Rollo, and Valeria Brown Presentation today by Ege Gungor Onal A vaccine targeting resistant tumours by dual T cell plus NK cell attack nature.com/articles/s4158… From lab of Dr. Kai

Attending The Warren Alpert Medical School #AMS_CRJC led today by medical students Ege Gungor Onal, Allegra Rollo, and Valeria Brown Presentation by Allegra Rollo on RCT’s in cancer medicine. Great presentation and discussion. Brown University Legorreta Cancer Center at Brown University #LegorretaCancerCenter

Attending The Warren Alpert Medical School #AMS_CRJC led today by medical students Ege Gungor Onal, Allegra Rollo, James He and Valeria Brown Presentation by Valeria Brown on TAp63 represses transcription of MYCN/NCYM gene and its high levels of expression are associated with favorable outcome in

Attending The Warren Alpert Medical School #AMS_CRJC led today by medical students Ege Gungor Onal, Allegra Rollo, and Valeria Brown Presentations by medical student Jacob Licht on pioneer factors like Brn2 that he got interested in during two years of research at National Cancer Institute in the Yawen Bai Lab